Adlai Nortye Ltd. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rectal cancer. The company also develops AN9025, an oral small molecule pan-RAS(ON) inhibitor, which is in phase 1a clinical trials for the treatment of RAS-mutant cancers, including pancreatic, lung, and colorectal adenocarcinomas; AN4035, a proprietary CEACAM5-targeting antibody drug conjugate designed to deliver potent anti-tumor activity with an improved therapeutic window; and AN8025, a tri-specific antibody fusion protein which is in phase Ia clinical trial to treat advanced tumors. In addition, it develops AN4005, a small-molecule PD-L1 inhibitor that demonstrates antitumor activity by the blockade of PD-1/PD-L1 interaction which is in phase 1b clinical trial to activate cancer immunity. Further, the company is involved in technology transfer and consulting services business. Adlai Nortye Ltd. was founded in 2004 and is headquartered in North Brunswick, New Jersey.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-30$10.63 RISE2026-03-27$6.46 PEAK2026-04-20$16.60 80d | -39.2% 56d | Missed | Missed | — | — | +157.0% 24d | Missed |
DROP2025-10-01$1.80 RISE2025-12-08$0.88 PEAK2026-01-30$10.63 121d | -51.1% 68d | Missed | Missed | — | — | +1108.0% 53d | Missed |
DROP2025-10-01$1.80 RISE2025-11-04$1.35 PEAK2026-01-30$10.63 121d | -25.0% 34d | Missed | Missed | — | — | +687.4% 87d | Missed |
DROP2025-03-24$2.33 RISE2025-07-30$1.41 PEAK2025-09-11$1.80 171d | -39.5% 128d | Missed | Missed | — | — | +27.7% 43d | Missed |
DROP2025-03-11$2.44 RISE2025-06-23$1.40 PEAK2025-09-11$1.80 184d | -42.6% 104d | Missed | Missed | — | — | +28.6% 80d | Missed |
DROP2024-12-31$2.69 RISE2025-04-21$1.71 PEAK2025-05-05$2.03 125d | -36.3% 111d | Missed | Missed | — | — | +18.4% 14d | Missed |
DROP2024-12-31$2.69 RISE2025-04-17$1.71 PEAK2025-05-05$2.03 125d | -36.3% 107d | Missed | Missed | — | — | +18.4% 18d | Missed |
DROP2024-11-08$3.54 RISE2025-01-06$1.95 PEAK2025-03-11$2.44 123d | -44.9% 59d | Missed | Missed | — | — | +25.0% 64d | Missed |
DROP2024-06-04$6.32 RISE2024-10-11$1.85 PEAK2024-11-08$3.54 157d | -70.7% 129d | Missed | Missed | — | — | +91.4% 28d | Missed |
DROP2024-06-04$6.32 RISE2024-10-10$1.85 PEAK2024-11-08$3.54 157d | -70.7% 128d | Missed | Missed | — | — | +91.4% 29d | Missed |
DROP2023-12-07$11.36 RISE2024-02-22$7.11 PEAK2024-04-29$14.80 144d | -37.4% 77d | Missed | Missed | — | — | +108.1% 67d | Missed |
DROP2023-09-29$15.00 RISE2023-11-02$7.85 PEAK2023-12-07$11.36 69d | -47.7% 34d | Missed | Missed | — | — | +44.7% 35d | Missed |
No scored news yet for a sentiment trend.
Oppenheimer analyst Jay Olson initiates coverage on Adlai Nortye (NASDAQ:ANL) with a Outperform rating and announces Price Target of $32.
Adlai Nortye Ltd. Sponsored ADR (ANL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Jones Trading analyst Boris Peaker initiates coverage on Adlai Nortye (NASDAQ:ANL) with a Buy rating and announces Price Target of $22.
Here is how AbCellera Biologics Inc. (ABCL) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
Here is how AbCellera Biologics Inc. (ABCL) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
Adlai Nortye Ltd. Sponsored ADR (ANL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Adlai Nortye Ltd. Sponsored ADR (ANL) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Adlai Nortye Ltd. (NASDAQ:ANL) is one of the best performing small cap stocks so far in 2026. On April 20, H.C. Wainwright lifted the price target on Adlai Nortye Ltd. (NASDAQ:ANL) to $20 from $16 while maintaining a Buy rating on the shares. The firm told investors in a research note that the company’s lead […]
Adlai Nortye Ltd. (NASDAQ:ANL) is one of the best performing small cap stocks so far in 2026. On April 20, H.C. Wainwright lifted the price target on Adlai Nortye Ltd. (NASDAQ:ANL) to $20 from $16 while maintaining a Buy rating on the shares. The firm told investors in a research note that the company’s lead […]
Adlai Nortye (NASDAQ:ANL) is one of the tiny stocks that are on fire right now. On April 16, Adlai Nortye entered into a securities purchase agreement for a private placement equity financing/PIPE expected to yield gross proceeds of ~$150 million. The oversubscribed transaction saw significant participation from a broad group of new and existing institutional […]
Adlai Nortye (NASDAQ:ANL) is one of the tiny stocks that are on fire right now. On April 16, Adlai Nortye entered into a securities purchase agreement for a private placement equity financing/PIPE expected to yield gross proceeds of ~$150 million. The oversubscribed transaction saw significant participation from a broad group of new and existing institutional […]
Here is how ANI Pharmaceuticals (ANIP) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
Here is how ANI Pharmaceuticals (ANIP) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.
Top analysts change outlook on top names: Truist cut Doximity's price target, Stifel raised Plexus's, Needham raised Cadence's, Mizuho slashed Skyworks'. HC Wainwright raised Adlai's, B of A Securities raised Corning's, Baird raised Autoliv's & Mizuho raised Robinhood's. See all analyst rating changes.
HC Wainwright & Co. analyst Joseph Pantginis maintains Adlai Nortye (NASDAQ:ANL) with a Buy and raises the price target from $16 to $20.
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
SINGAPORE and NORTH BRUNSWICK, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (Nasdaq: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $150.0 million, before deducting placement agent fees and other private plac
Adlai Nortye Ltd.has entered into a securities purchase agreement to issue 11,320,755 American Depositary Shares at a price of $13.25 per for gross proceeds of $150,000,003.75 on April 16, 2026. The ...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ANL | -22.97% | +44.90% | +740.85% | +556.04% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -25.94% | +50.62% | +744.29% | +543.36% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 66.0K | $456.72K | 0.00% | New | 2026-03-31 |
| TRowePrice | fundamental | 99.8K | $691 | 0.00% | New | 2026-03-31 |